Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.The Japanese pharma isn’t abandoning the project just yet, though, as it says the study in Dravet syndrome only narrowly missed its primary endpoint and showed efficacy on secondary endpoints. It originated the drug and licensed it to Ovid Therapeutics, before taking it back in-house in 2021 in a deal worth up to $850 million.
